Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in Australia. The company focuses on the development and commercialization of medical devices using its NovoSorb technology in the treatment of burns, surgical wounds, and negative pressure wound therapy. It offers BTM (biodegradable temporising matrix), a wound dressing intended for treatment of full-thickness wounds and burns. In addition, Polynovo Limited licensed its NovoSorb to Smith & Nephew for orthopaedic applications. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 8681 4050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.04 million
Profitability
Miscellaneous
Employees41
Next Earnings DateN/A
OptionableNot Optionable
Polynovo (ASX:PNV) Frequently Asked Questions
What is Polynovo's stock symbol?
Polynovo trades on the ASX under the ticker symbol "PNV."
Has Polynovo been receiving favorable news coverage?
Media stories about PNV stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Polynovo earned a news impact score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Polynovo.
Who are some of Polynovo's key competitors?
Some companies that are related to Polynovo include Cronos Group (CRON), MorphoSys (MOR), BTG (BTG), MorphoSys (MOR), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Clinuvel Pharmaceuticals (CUV), Vir Biotechnology (VIR), Concordia International (CXR), Mesoblast (MSB), Kodiak Sciences (KOD), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU) and Biotest (BIO).
What other stocks do shareholders of Polynovo own?
Who are Polynovo's key executives?
Polynovo's management team includes the folowing people:
- Mr. Paul Brennan, Chief Exec. Officer
- Mr. Greg Lewis M.A.I.C.D., M.B.A., Chief Operating Officer
- Mr. Jan-Marcel Gielen, CFO & Company Sec.
- Dr. Tim Moore, Principal Scientist
- Mr. David Smith, Manufacturing Mang.
What is Polynovo's stock price today?
One share of PNV stock can currently be purchased for approximately A$2.44.
How big of a company is Polynovo?
What is Polynovo's official website?
How can I contact Polynovo?
The company can be reached via phone at 61 3 8681 4050.
MarketBeat Community Rating for Polynovo (ASX PNV)
MarketBeat's community ratings are surveys of what our community members think about Polynovo and other stocks. Vote "Outperform" if you believe PNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
